KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes...<< Prices as on Jun 20, 2024 - 3:59PM >>  ABB India 8542.9  [ 0.02% ]  ACC 2626.9  [ 0.26% ]  Ambuja Cements 659.15  [ -1.12% ]  Asian Paints Ltd. 2918  [ 0.88% ]  Axis Bank Ltd. 1237.9  [ 0.95% ]  Bajaj Auto 9622.1  [ -0.68% ]  Bank of Baroda 285.2  [ 0.48% ]  Bharti Airtel 1381.15  [ -0.86% ]  Bharat Heavy Ele 293.4  [ -1.21% ]  Bharat Petroleum 626.3  [ 1.66% ]  Britannia Ind. 5384.8  [ 0.46% ]  Cipla 1547.95  [ -0.73% ]  Coal India 483.15  [ 1.04% ]  Colgate Palm. 2859.6  [ -1.20% ]  Dabur India 600.7  [ 0.38% ]  DLF Ltd. 874.4  [ 1.70% ]  Dr. Reddy's Labs 5973  [ 0.31% ]  GAIL (India) 218.55  [ 1.02% ]  Grasim Inds. 2500  [ 2.14% ]  HCL Technologies 1446  [ 0.07% ]  HDFC 2729.95  [ -0.62% ]  HDFC Bank 1669  [ 0.66% ]  Hero MotoCorp 5513.2  [ -2.32% ]  Hindustan Unilever L 2478.1  [ 0.85% ]  Hindalco Indus. 676.75  [ 2.16% ]  ICICI Bank 1156.8  [ 1.05% ]  IDFC L 123.75  [ 2.19% ]  Indian Hotels Co 638.3  [ 3.46% ]  IndusInd Bank 1529  [ -0.03% ]  Infosys L 1515.3  [ 0.26% ]  ITC Ltd. 423.35  [ -0.08% ]  Jindal St & Pwr 1056.65  [ 0.93% ]  Kotak Mahindra Bank 1765.05  [ 0.96% ]  L&T 3597.1  [ 0.19% ]  Lupin Ltd. 1555.1  [ -1.12% ]  Mahi. & Mahi 2870.7  [ -2.10% ]  Maruti Suzuki India 12143.9  [ -0.75% ]  MTNL 41.71  [ -1.00% ]  Nestle India 2538  [ 0.51% ]  NIIT Ltd. 104.6  [ 2.25% ]  NMDC Ltd. 273.2  [ 4.24% ]  NTPC 357.9  [ -1.26% ]  ONGC 271.85  [ 0.11% ]  Punj. NationlBak 128.5  [ 0.19% ]  Power Grid Corpo 324.6  [ -0.90% ]  Reliance Inds. 2946.4  [ 1.00% ]  SBI 843.8  [ -1.03% ]  Vedanta 470.25  [ 4.86% ]  Shipping Corpn. 273.15  [ -0.51% ]  Sun Pharma. 1470.45  [ -2.24% ]  Tata Chemicals 1153.2  [ 4.23% ]  Tata Consumer Produc 1105.65  [ -0.04% ]  Tata Motors 978.1  [ 0.07% ]  Tata Steel 182.35  [ 1.28% ]  Tata Power Co. 444.2  [ 0.43% ]  Tata Consultancy 3786.6  [ -0.38% ]  Tech Mahindra 1392.1  [ 0.79% ]  UltraTech Cement 10951.5  [ -0.36% ]  United Spirits 1269  [ -0.23% ]  Wipro 490.5  [ -1.03% ]  Zee Entertainment En 155.55  [ 0.78% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

CIPLA LTD.

20 June 2024 | 04:06

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE059A01026 BSE Code / NSE Code 500087 / CIPLA Book Value (Rs.) 289.87 Face Value 2.00
Bookclosure 02/08/2024 52Week High 1582 EPS 51.04 P/E 30.27
Market Cap. 124749.42 Cr. 52Week Low 986 P/BV / Div Yield (%) 5.33 / 0.84 Market Lot 1.00
Security Type Other

AUDITOR'S REPORT

You can view full text of the latest Director's Report for the company.
Year End :2023-03 

To the Members of Cipla Limited

Report on the Audit of the Standalone Financial StatementsOpinion

1. We have audited the accompanying standalone financial statements of Cipla Limited ('the Company'), which comprise the Balance Sheet as at 31st March, 2023, the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flow and the Statement of Changes in Equity for the year then ended, and notes to the standalone financial statements, including a summary of the significant accounting policies and other explanatory information.

2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards ('Ind AS')

specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2023, and its profit (including other comprehensive income), its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

4. Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matters

How our audit addressed the key audit matters

DPCO matters:

Our

audit of DPCO matters included, but was not limited to, the

The Company is regulated by National Pharmaceutical Pricing

following procedures:

Authority, Government of India (NPPA). There are a number of legal and regulatory cases, of which the most significant Drugs (Prices Control) Orders (DPCO) as disclosed in Note 38B (ii) to the standalone financial statements, relating to overcharging of certain drugs under DPCO.

a)

Obtained an understanding of the management's process for updating the status of the matters, assessment of accounting treatment in accordance with Ind AS 37, and for measurement of amounts involved;

According to NPPA's public disclosure, the total demand against the Company aggregates to H 3,703.40 crores as at 31st March, 2023, of which:

b)

Evaluated the design and tested the operating effectiveness of key controls around above process;

a) H 3,456.39 crores relates to matters pending at Honourable Bombay High Court, wherein the Holding Company has deposited H 175.08 crores being 50% of the total demand of H 350.15 crores as at 1st August, 2003 under protest pursuant to direction of Honourable Supreme Court of India; and

c)

Inspected correspondence with the Company's external legal counsel in order to corroborate our understanding of these matters, accompanied by discussions with both internal and external legal counsels. Tested the objectivity and competence of such management experts involved;

b) H 247.01 crores relates to other matters, wherein based on facts and legal advice, the Company has recorded a charge of H 6.89 crores (including interest) during the year ended 31st March, 2023 and carries a total provision of H 125.38 crores (including interest) as at 31st March, 2023.

The amounts involved are material and the application of accounting principles as given under Ind AS 37, Provisions, Contingent Liabilities and

d)

Obtained direct confirmation from the external legal counsel handling DPCO matters with respect to the legal determination of the liability arising from such matters, conclusion of the matters in accordance with the requirements of Ind AS 37 and disclosures to be made in the financial statements. Evaluated the response received from the external legal counsel to ensure that the conclusions reached are supported by sufficient legal rationale;

Contingent Assets ('Ind AS 37'), in order to determine the amounts to be recognised as liability or to be disclosed as a contingent liability or not, is inherently subjective and needs careful evaluation and significant judgement to be applied by the management.

e)

Assessed the appropriateness of methods used, and the reliability of underlying data for the calculations made for quantifying the amounts involved. Tested the arithmetical accuracy of such calculations; and

Key audit matters

How our audit addressed the key audit matters

Considering the materiality and the inherent subjectivity which involves

f) Evaluated the Company's disclosures for adequate disclosure

significant management judgment in predicting the outcome of the

regarding the significant litigations of the Company.

matter, DPCO matters have been considered to be a key audit matter for

Based on the audit procedures performed, the judgements made by

the current period audit.

the management were reasonable and disclosures made in respect of these matters were appropriate in the context of the standalone financial statements taken as a whole.

Recoverability of investments in subsidiaries:

Our audit included, but was not limited to, the following procedures:

The Company has investments of H 9,029.34 crores in subsidiaries

a) Obtained an understanding of the management's process for

being carried at cost in accordance with Ind AS 27, Separate Financial

identification of impairment indicators and tested the design

Statements. The Company assesses the recoverable amounts of each

and operating effectiveness of internal controls over such

investment when impairment indicators exist by comparing the fair

identification and impairment measurement through fair

value (less costs of disposal) and carrying amount of that investment as

valuation of identified investments;

on the reporting date.

b) Involved auditor's experts to assess the appropriateness of the

The Company has recorded an impairment loss on investment in SABA

valuation methodologies used by the management;

Investment Limited of H 185.90 crores during the year ended 31st March,

c) Reconciled the cash flows to the business plans approved by

2023. Refer note 5 to the standalone financial statements.

the respective Board of Directors of the identified investee

Management's assessment of whether there are impairment indications

companies;

and estimate of the recoverable amounts of the identified investments

d) Evaluated and challenged management's assumptions such as

determined through discounted cash flow valuation method requires

implied growth rates during explicit period, terminal growth rate,

significant judgment in carrying out the impairment assessment. The

targeting savings and discount rate for their appropriateness

key assumptions used in management's assessment of the recoverable

based on our understanding of the business of the respective

amounts include, but are not limited to, projections of future cash

investee companies, past results and external factors such as

flows, growth rates, discount rates, estimated future operating and

industry trends and forecasts, including the possible impact of

capital expenditure. Changes to these assumptions could lead to material changes in estimated recoverable amounts, resulting in either impairment or reversals of impairment taken in prior years.

COVID -19 pandemic on such assumptions; e) Obtained and evaluated sensitivity analysis performed by the management on key assumptions of implied growth rates during

Considering the materiality and the inherent subjectivity which involves significant management judgment in predicting future cash flow projections, recoverability of investments in subsidiaries has been considered to be a key audit matter for the current period audit.

explicit period, terminal growth rates and discount rates;

f) Tested the mathematical accuracy of the management computations with regard to cash flows and sensitivity analysis;

g) Performed independent sensitivity analysis of aforesaid key assumptions to assess the effect of reasonably possible variations on the current estimated recoverable amount for each of the identified investments to evaluate sufficiency of headroom between recoverable value and carrying amount; and

h) Evaluated the adequacy of disclosures given in the standalone financial statements, including disclosure of significant assumptions, judgements and sensitivity analysis performed, in accordance with applicable accounting standards.

Based on the audit procedures performed, we determined that the management's assertion on the recoverability of investments in subsidiaries is appropriate in the context of the standalone financial statements taken as a whole.

Revenue from operations: (refer note 1.13 and 26 to the Standalone

Our audit included, but was not limited to, the following procedures:

financial statements)

a) Obtained an understanding of the management's process for

The Company recognises revenue from the sales of pharmaceutical

revenue recognition (from sale to customers, out-licensing

products to resellers or distributors, out-licensing arrangements and

arrangements and service fee), judgments in estimation and

service fee. The Company recognises revenue from product sales when

accounting treatment of discount schemes, returns, rebates and

control of the product transfers, generally upon shipment or delivery

regulatory compliance requirements;

Key audit matters

How our audit addressed the key audit matters

to a customer. The Company records product sales net of estimated incentives/discounts, returns, rebates and other related charges. The actual point in time when revenue is recognised varies depending on the specific terms and conditions of the sales contracts entered with customers.

b)

Evaluated the design and tested the operating effectiveness of the Company's internal controls, including general IT controls, key IT application controls exercised by the management, over recognition of revenue and measurement of various discount schemes, returns and rebates;

Further, the Company has a large number of customers operating in various geographies and sales contracts with customers have a variety of different terms relating to the recognition of revenue, the entitlement to sales rebates, the right to return and price adjustments. Sales arrangements in certain jurisdictions lead to material deductions to

c)

Evaluated the terms of the licensing arrangements to determine satisfaction of performance obligations under the contracts for appropriate revenue recognition and tested allocation of consideration between performance obligations to verify deferral of revenue in respect of unsatisfied performance obligations;

gross sales in arriving at revenue.

The Company also has development and commercialisation arrangements relating to research and development of new products. This includes in-licensing and out-licensing arrangements and other types of complex agreements. We identified recognition of revenue

d)

Performed substantive testing by selecting samples of revenue transactions pertaining to sale of products during the year, and verified the underlying supporting documents including contracts, agreements, sales invoices and dispatch/shipping documents;

from operations as a key audit matter because:

a) Accrual towards rebates, discounts, returns and allowances is complex and requires significant judgments and estimates in relation to contractual agreements/ commercial terms across

e)

Performed cut-off testing procedures by testing samples of revenue transactions recorded during the year in specific periods before and after year end to conclude there has not been overstatement/ understatement of revenue recorded for the year;

various geographies. Any change in these estimates can have a significant financial impact.

b) The nature of development and commercialisation arrangements are often inherently complex and unusual, requiring significant management judgment to be applied in respect of revenue recognition.

c) The Company considers revenue as key benchmark for evaluating

f)

Obtained management workings for amounts recognised towards discount schemes, returns and rebates during the year and as at year end. On a sample basis, tested the underlying calculations for amounts recorded as accruals and provisions towards the aforementioned obligations, as per the terms of related schemes, contracts and regulations, and traced the underlying data to source documents;

performances and hence, there is risk of revenue being overstated due to pressure to achieve targets, earning expectations or incentive schemes linked to performance for a reporting period.

g) Evaluated historical accuracy of the Company's estimates of year-end accruals pertaining to aforesaid arrangements made in the previous years to identify any management bias;

h) Tested all the manual sales-related adjustments made to revenue comprising of variable consideration under Ind AS 115 to ensure the appropriateness of revenue recognition during the year; and

i) Evaluated the adequacy of disclosures in the standalone financial statements.

Based on audit procedures performed, we determined that the revenue recognition and measurement is appropriate in the context of the standalone financial statements taken as a whole.

Information other than the Financial Statements and Auditor's Report thereon

5. The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

10. As part of an audit in accordance with Standards on Auditing, specified under section 143(10) of the Act we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

• Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;

• Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern;

• Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation;

11. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

6. The accompanying standalone financial statements have been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Act with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS specified under section 133 of the Act and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

7. In preparing the financial statements, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

8. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

9. Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

12. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

13. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

14. As required by section 197(16) of the Act based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.

15. As required by the Companies (Auditor's Report) Order, 2020 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act we give in the Annexure I a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

16. Further to our comments in Annexure I, as required by section 143(3) of the Act based on our audit, we report, to the extent applicable, that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying standalone financial statements;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

c) The standalone financial statements dealt with by this report are in agreement with the books of account;

d) In our opinion, the aforesaid standalone financial statements comply with Ind AS specified under section 133 of the Act;

e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of section 164(2) of the Act;

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company as on 31st March, 2023 and the operating effectiveness of such controls, refer to our separate Report in Annexure II wherein we have expressed an unmodified opinion; and

g) With respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:

i. the Company, as detailed in note 38 to the standalone financial statements, has disclosed the impact of pending litigations on its financial position as at 31st March, 2023.;

ii. As detailed in note 52, the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31st March, 2023;

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company during the year ended 31st March, 2023;

iv. a. The management has represented that, to the best

of its knowledge and belief, other than as disclosed in note 44 (j) and note 44 (k) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or securities premium or any other sources or kind of funds) by the Company to or in any person(s) or entity(ies), including foreign entities ('the intermediaries'), with the understanding, whether recorded in writing or otherwise, that the intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ('the Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf the Ultimate Beneficiaries;

b. The management has represented that, to the best of its knowledge and belief, as disclosed in note 44 (f) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ('the Funding Parties'), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether directly or indirectly, lend or invest in other persons or entities identified

in any manner whatsoever by or on behalf of the Funding Party ('Ultimate Beneficiaries') or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c. Based on such audit procedures performed as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the management representations under sub-clauses (a) and (b) above contain any material misstatement.

v. a. The final dividend paid by the Company during the year ended 31st March, 2023 in respect of such dividend declared for the previous year is in accordance with section 123 of the Act to the extent it applies to payment of dividend.

b. As stated in note 47 (B) (b) to the accompanying standalone financial statements, the Board of Directors of the Company have proposed final dividend for the year ended 31st March, 2023 which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with section 123 of the Act to the extent it applies to declaration of dividend.

vi. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 requires all companies which use accounting software for maintaining their books of account, to use such an accounting software which has a feature of audit trail, with effect from the financial year beginning on 1st April, 2023 and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 (as amended) is not applicable for the current financial year.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Ashish Gupta

Partner

Membership No.: 504662

UDIN: 23504662BGWGDY8126

Place: New Delhi

Date: 12th May, 2023